Atovaquone (Mepron) is a fibrate-class lipid-lowering medicationNational Center for Biotechnology Information. Proper use and a healthy lifestyle are critical to maximizing therapeutic efficacy and minimizing risks.

I. Dosage and Administration of Atovaquone (Mepron)

1. Standard Adult Dosage

(1) The usual adult dose is 106.6 mg to 160 mg orally once daily, taken with meals.

(2) Dosage should be adjusted appropriately based on age and symptoms; the total daily dose must not exceed 160 mg.

2. Dosage Adjustment by Hyperlipidemia Type

(1) Type IIb and Type III (elevated cholesterol and triglycerides): Start with 106.6 mg daily. If there are risk factors for ischemic heart disease, the dose may be increased to 159.9 mg–160 mg.

(2) Type IV and Type V (predominantly elevated triglycerides): May start with a low dose of 53.3 mg daily, which has been shown to be effective in studies.

(3) Patients with abnormal liver function or a history of liver disease: Start with 53.3 mg daily.

3. Dosage Adjustment for Renal Impairment

(1) Serum creatinine 1.5–2.5 mg/dL or CCr 40–60 mL/min: Start with 53.3 mg, or extend the dosing interval.

(2) Serum creatinine ≥ 2.5 mg/dL or CCr < 40 mL/min: Contraindicated.

4. Special Populations

(1) Elderly patients: Start with 53.3 mg and closely monitor renal function.

(2) Pediatric patients: Not recommended due to lack of clinical data.

(3) Pregnant and lactating women: Contraindicated.

II. Precautions for Atovaquone (Mepron) Use

1. Necessary Examinations Before Treatment

(1) Lipid levels should be thoroughly assessed before initiating therapy; use only after confirming hyperlipidemia.

(2) Evaluate hepatic and renal function simultaneously to ensure eligibility for treatment.

2. Monitoring Requirements During Treatment

(1) Liver function: Recheck monthly for the first 3 months, then every 3 months thereafter. Discontinue treatment if AST or ALT persistently exceeds 2.5 times the upper limit of normal or 100 units.

(2) Renal function: Monitor serum creatinine regularly, especially in elderly and high-risk patients.

(3) Creatine kinase: Test promptly if muscle symptoms occur.

3. Management of Missed and Overdosed Doses

(1) Missed dose: Take as soon as possible with a meal; if it is nearly time for the next dose, skip the missed dose and take the next one on schedule. Do not double the dose.

(2) Overdose: Monitor closely for symptoms such as muscle pain and nausea; seek medical attention if necessary. Due to high protein binding, hemodialysis is ineffective for drug removal.

III. Healthy Lifestyle for Patients Taking Atovaquone (Mepron)

1. Basic Dietary Therapy

(1) Hyperlipidemia treatment should be based on dietary management.

(2) Maintain a low-fat, low-cholesterol diet and control total caloric intake before and during medication.

2. Regular Exercise

Combine with appropriate exercise therapy, such as at least 150 minutes of moderate-intensity aerobic exercise weekly, to help improve lipid levels and control weight.

3. Risk Factor Management

(1) Blood pressure control: Hypertensive patients should actively manage blood pressure.

(2) Smoking cessation: Smoking is a major risk factor for ischemic heart disease; smoking cessation is recommended.

(3) Alcohol restriction: Excessive alcohol consumption may affect lipid levels and liver function.

4. Weight Management

Maintain a healthy weight. Overweight or obese patients should lose weight appropriately through diet and exercise to improve lipid metabolism.

5. Regular Follow-Ups

Even if feeling well, attend scheduled follow-ups to recheck lipid levels, hepatic and renal function, assess treatment efficacy, and detect potential issues promptly.

6. Uric Acid Management

Studies show atovaquone has a uric acid-lowering effect in hyperlipidemic patients with hyperuricemia; monitor changes in uric acid levels.